Do you have safety concerns when prescribing GLP-1 medications in patients on corticosteroids or immunosuppressive therapy?

This question is part of our collaboration with ACR Convergence 2025 to preview a session from this year's meeting. This question is inspired by the upcoming session "GLP1 Agonists in Rheumatic Disease and Osteoarthritis: Should We Give Them to Everyone?" by Dr. C. Thomas Appleton and Dr. @Francis Berenbaum.

Answer from: at Community Practice

I think we need to be particularly careful when co-prescribing with systemic corticosteroids because of the risk of sarcopenia. We know that rapid weight loss is accompanied not only by a loss of fat tissue but also of muscle. Corticosteroids can also have myotoxicity and cause muscle atrophy. I the...

Comments

at U.S. Department of Veterans Affairs
Steroid reduction and concomitant inc protein inta...

Please select the option that best describes you:

Do you have safety concerns when prescribing GLP-1 medications in patients on corticosteroids or immunosuppressive therapy?

Related Questions